Aims: To assess the role of MDR1 and gamma-aminobutyric acid receptor-gamma 2 sub unit (GABRG2) gene polymorphism in seizure susceptibility in generalized seizure (GS) and febrile seizure (FS) patients and to evaluate MDR1 C3435T gene polymorphism's role in absorption of the anti-epileptic drug, phenytoin (PHT) in a cohort of patients. Methods: One hundred twenty-seven cases of seizure (86 GS and 41 FS) patients were analyzed for MDR1 C3435T and GABRG2 C588T gene polymorphisms using restriction fragment length polymorphismpolymerase chain reaction. Serum PHT levels were analyzed. Results: The T allele of MDR1 C3435T and GABRG2 C588T gene polymorphism was significantly associated with GS in the Indian population ( p < 0.05) compared with controls. From the data in GS, CT and TT genotype carriers of the MDR1 gene and TT genotype carriers of the GABRG2 gene had more recurrent seizures compared with others. MDR1 T allele carriers in the seizure reoccurrence (SR) group of GS and FS were high compared with the well-controlled seizure group (with no seizures after treatment). TT genotype carriers in SR group were high in FS (with regard to MDR1 gene polymorphism) and GS (with regard to GABRG2 gene polymorphism) compared with a well-controlled seizure group. MDR1 C3435T gene polymorphism affects serum PHT levels ( p < 0.015). Association of dose PHT ratio and genotype groups of MDR1 C3435T gene polymorphism showed a significant association ( p < 0.05). MDR1*CC genotype was more common in cases with low serum PHT levels.In addition, it is evident that CT and TT genotype carriers have a high percentage of SR with elevated serum PHT levels. Conclusions: Our results show that the MDR1 3435T and GABRG2 588T alleles play a role in seizure occurrence. Moreover, the MDR1 3435T allele also affects PHT absorption. We suggest MDR1 C3435T and GABRG2 C588T genotyping would be of value in order to lower the risk of concentration-dependent drug toxicity and for better patient management.
Introduction

E
pilepsy is a common chronic neurological condition that is characterized by recurrent unprovoked seizures. Two most common seizure types are generalized seizures (GS) affecting adults and febrile seizures (FS) affecting children.
MDR1 functions in an energy-dependent manner by exporting substances from the inside of cells to the outside. MDR1 and other transporters form an important class of proteins for regulating pharmacokinetics. MDR1 exports a number of structurally unrelated drugs (Marzolini et al., 2004; Pauli-Magnus and Kroetz, 2004) . They play an important role in selective absorption and elimination of endogenous substances and xenobiotics, including drugs (Kim, 2002) . Decreased expression of MDR1 due to alteration in the gene is known to affect the response of antiepileptic drugs (AEDs) (Amara and Sonders, 1998) .
Neurotransmitters are chemicals that transmit signals between neurons as well as between neurons and other cell types (Bear et al., 2011) . Gamma-aminobutyric acid (GABA) and glutamate are the two major neurotransmitters of the brain. The majority of receptors are abg and abd isoforms, a1b2g2 subunit combination is the most abundant in the brain (Sieghart et al., 1999; Whiting, 2003) . The importance of specific aspects of GABR function in the maintenance of central synaptic inhibition is well documented (Baulac et al., 2001; Wallace et al., 2001) . Impaired GABAergic function contributes to certain forms of epilepsy, schizophrenia, alzheimer's disease, and other neurological disorders. GABRG2 (a exonic gamma-aminobutyric acid receptor-gamma 2 sub unit) C588T gene polymorphism has been associated with susceptibility to variety of seizures (Chou et al., 2007; Kang et al., 2009; Kumari et al., 2010) .
The present study aimed at evaluating whether the MDR1 C3435T gene polymorphism plays a role in seizure occurrence in GS and FS and to understand its effect on clinical pharmacokinetics of phenytoin (PHT) in patients. It also aimed at evaluating the GABRG2 C588T gene polymorphism to understand the susceptibility to GS and FS in our population.
Materials and Methods
Patient recruitment
A total of 127 cases were included for the study groups just mentioned. Of these, 41 infants/children with FS below the age of 5 years were selected based on the clinical symptoms and electroencephalogram findings. Another 86 cases with GS were recruited (generalized tonic seizures, generalized clonic seizures, and generalized tonic clonic seizures) from the neurology department. The cases with GS were included based on the clinical symptoms, magnetic resonance imaging, electro-encephalogram, and computer tomography scan findings. The epilepsies and epileptic syndromes were diagnosed based on the revised ''Classification of Epilepsies and Epileptic syndromes of the International League Against Epilepsy' ' (International League Against Epilepsy, 1989) . Fiftyone randomly selected healthy volunteers and 49 patients with head injury cases without any history of neurological diseases or a family history of any neurological problem were included as normal controls. Clinical, personal, and family history of the patients were obtained in a well-designed proforma. Table  1 shows demographic details of the cases studied. The institutional ethical committee approved this study. 
Blood collection
A 1 mL peripheral blood sample with 0.1 mL heparin was collected in a syringe. DNA was isolated from all these samples according to the standard procedure followed in the lab; and stored at -20°C until further use (Ponnala et al., 2009) .
For serum PHT analysis, 3 mL of plain blood sample was collected in a sterile plain vacutainer from 108 cases 2 h after drug intake. The sample was left for about 10 min at room temperature and then spun down in a centrifuge for 10 min at 1000 rpm. The serum was then separated and analyzed for PHT levels immediately by the homogenous-particleenhanced turbidimetric inhibition immunoassay technique.
MDR1 C3435T and GABRG2 C588T gene polymorphism analysis MDR1 C3435T gene was amplified by using 5¢ TTGA TGGCAAAGAAATAAAGC 3¢ (forward) and 5¢ CTTACA TTAGGCAGTGACTCG 3¢ (reverse) primers and GABRG2 gene by using 5¢ CCATCTTATGTTTAATATCTTTCT 3¢ (forward) and 5¢AATCAGAAAGACTGTAGGTGAGG 3¢ (reverse) primers (Kananura et al., 2002) . polymerase chain reaction (PCR) was set up using the PCR cycle (95°C for 5 min, [95°C for 30 s, 56°C for 30 s, and 72°C for 30 s] · 30 cycles, 72°C for 10 min). The wild-type allele of MDR1 is C, and the mutant is T. The C3435T substitution generates a MboI restriction recognition sequence (Cat No. ER0811; Fermentas), and restriction digestion gives two fragments of 206 and 130 bp. Normal homozygotes were identified by the presence of a 130 bp fragment, mutated homozygotes by the presence of a 206 bp fragment, and heterozygotes by the presence of both fragments (Fig. 1) . The nucleotide change from C to T at 588 position in the GABRG2 gene creates a restriction site for the TasI restriction enzyme (Cat No. ER1351; Fermentas). The wildtype allele of GABRG2 is C, and the mutant is T. The C588T substitution generates a TasI restriction recognition sequence, and restriction digestion gives fragments of the following sizes: 109 + 36 + 17 + 6 bp (C allele) and 101 + 36 + 17 + 6 + 8 bp (T allele). However, < 100 bp fragments are not seen on the gel (Fig. 2) .
Statistical analysis
All the data was analyzed using the SPSS for 
Results
MDR1 C3435T gene polymorphism
In this study, the distribution and analysis of genotype and allele frequencies of MDR1 C3435T gene polymorphism of GS and FS cases were assessed along with the controls (Table 2) . Table 2 shows a higher percentage of CT and TT genotype carriers of MDR1 C3435T polymorphism in GS compared with the controls. However, CT genotype carriers were high in FS cases compared with the controls. Statistical analyses for genotype models showed no significant association ( p > 0.05) ( Table 3) .
T allele frequency was higher in GS compared with FS and controls (Table 2) . Pooled allele frequency of MDR1 C3435T gene polymorphism was 0.38 of C allele and 0.62 T allele in the cohort studied, which was similar to the earlier reported frequency in the Indian population (Table 4 ). In the present study group, the MDR1 C3435T genotype frequency followed Hardy-Weinberg equilibrium (Calculated v 2 = 1.14 < 3.84 at 5% level significance for first degree of freedom).
Variations in drug absorption, drug targets, and metabolism between individuals are involved in uncontrolled seizures. Therefore, the present study was undertaken to determine the impact of MDR1 C3435T gene polymorphism in seizure reoccurrence (SR) of GS and FS types (Table 5) . 45.34% (39/86) cases of GS and 41.46% (17/41) cases of FS had SR. From the data, CT and TT genotype carriers of SR of GS were high compared with others (Table 5 ). However, in FS cases, TT genotype carriers in the SR group were high compared with the well-controlled seizure group (Table 5) . Allele frequency of SR and controlled seizures of GS and FS was not statistically significant (OR = 1.43 95% confidence interval [CI] = 0.76 to 2.69 and OR = 1.18 95% CI = 0.48 to 2.86 respectively). However, T-allele carriers in the SR group of GS and FS were high compared with well-controlled seizures (Table 5) .
MDR1 plays a critical role in the development of resistance to anticancer drugs, antiviral agents, and anticonvulsants (Anglicheau et al., 2003; Sakaeda et al., 2003) . In the present study, pharmacoresistant epilepsy indicated by SR was evaluated in GS and FS types. We observed well-controlled GS compared with the SR group, which showed v 2 = 5.739, p < 0.05, indicating the protective role of the MDR1 C3435 allele in controlling SR (Table 5) . SR observed in CT and TT genotype carriers of GS and TT genotype carriers of FS cases could have a high risk of developing seizures compared with others. This is the first study from the Indian population where the role of MDR1 gene polymorphism and its contribution to seizure occurrence in GS and FS was assessed. Further, evaluation of 108 patients for serum PHT levels along with MDR1 C3435T gene polymorphism showed a gradual increase in mean serum PHT levels from homozygous C allele, heterozygous CT, and homozygous T allele (Fig.  3A) . In this study, 12.03% (13/108) CC, 49.07% (53/108) CT, and 38.88% (42/108) TT genotype carriers were present. Genotype and serum PHT level analysis in cases showed that the MDR1 C3435T gene polymorphism affects serum PHT levels (Pearson Correlation 0.230 p < 0.015). A non-parametric Kruskal-Wallis test was performed to compare the dose PHT ratio and genotype groups of MDR1 C3435T. It showed a significant association (v 2 = 8.14; p = 0.01). The MDR1*CC genotype was more common in cases with low PHT levels. The mean serum PHT levels in SR genotype groups were 8.65, 9.51, and 17.54 mg/mL for CC, CT, and TT genotypes, respectively. Inter-individual variation in serum PHT levels with genotype groups of MDR1 C3435T polymorphism was also observed in this study (Fig. 3B) . In this study, cases were evaluated for SR in individual MDR1 C3435T genotype groups; 15.38% (2/13) CC, 30.18% (16/53) CT, and 45.23% (19/42) TT genotype carriers had SR. From the data, it is evident that CT and TT genotype carriers have a high percentage of SR and also elevated serum PHT levels; this may suggest that the presence of the T allele plays a role in SR by MDR1 over-expression.
GABRG2 C588T gene polymorphism
In this analysis, 23/86 (26.74%) cases of GS and 7/41 (17.48%) cases of FS had a positive family history of seizures. The distribution and analysis of genotype and allele frequencies of GS and FS cases was assessed along with controls (Table 6 ). Statistical analyses carried out with different genotype models indicate no association with both seizure types studied (Table 7 ). The allele distribution was statistically significant with the ''T'' allele being associated with GS in our population ( p < 0.05) ( Table 7) . When the allele frequencies of GS and FS were combined and compared with controls, it showed a significant association of the T allele with seizures ( p < 0.05). Table 8 shows the association of the GABRG2 C588T gene polymorphism in different seizure types. Distributions of genotype and allele frequency of GABRG2 C588T polymorphism in controls in the present study were similar to the frequency reported by Kananura et al. (2002) in the German population (Table 8 ). However, a slightly higher percentage of cases was observed in TT genotype carriers (Table 6) .
In this study, the association of the GABRG2 C588T gene polymorphism was assessed in GS and FS patients with SR (Table 9 ). About 45.34% (39/86) GS and 41.46% (17/41) FS cases had SR. TT genotype carriers were high in the recurrent seizure group of GS compared with the well-controlled GS (with no seizures after treatment); however, this was not statistically significant (Table 9) . Compared with GS, in FS, CT genotype carriers were high in the recurrent seizure group (Table 9) . However, none of the SR cases of FS carried the TT genotype. SR cases when compared with controlled seizures cases of both GS and FS did not show a significant change in distribution of genotype or allele frequency (Table 9) .
Discussion
Epilepsy is a common neurological disorder affecting 1% of people worldwide, it is estimated that 40% of them have a genetic basis. In the Indian population, the prevalence is 5.5 per 1000 (Das et al., 2006) . The MDR1 transporter is a Pglycoprotein that regulates exchange of xenobiotics between plasma/brain in normal brain; however, in the epileptic brain, MDR1 levels are abnormal in the epileptic region leading to altered penetration/distribution of drugs (Sisodiya et al., 2002; Marchi et al., 2004) . The mechanism of pharmacoresistance in epilepsy is poorly understood and accounts for much of the economic burden of epilepsy (Regesta and Tanganelli, 1999) . The MDR1 C3435T gene polymorphism was reported to alter the drug response in humans and contribute to pharmacoresistant epilepsy. In view of this, in the present study of GS, FS patients along with controls were assessed for the MDR1 C3435T gene polymorphism. The MDR1 C3435T gene polymorphism in the present study followed Hardy-Weinberg equilibrium, similar to the earlier reported data from India (Balram et al., 2003; Ramasamy et al., 2006) . A higher percentage of T-allele carriers in SR of GS and FS cases are observed. Presence of the T allele might lead to over-expression of MDR1 in endothelial cells in the blood brain barrier. This was supported by the earlier observation where 3435T allele was associated with overexpression of MDR1 . Another study from Japan reported higher MDR1 mRNA expression in the TT genotype of MDR1 C3435T variant . Active efflux of AEDs (substrates of MDR1) from endothelial cells back into the blood may cause lowered levels of these AEDs in the brain and could result in recurrent seizures. An earlier report by Regesta and Tanganelli (1999) showed that decreased drug uptake in the brain because of altered expression of MDR1 transporters affects the transport of drug across the blood-brain barrier and results in drug resistance. Other researchers also reported MDR1 3435T allele and TT genotype association with drug-resistant epileptic patients with recurrent seizures in the Asian population (Seo et al., 2006; Kwan and Brodie, 2007) .
CT and TT genotype carriers of GS and TT genotype carriers of FS cases could have a higher risk of developing seizures compared with others. This is one of the very few studies from the Indian population, wherein the role of the MDR1 gene polymorphism and its contribution to seizure occurrence in GS and FS were assessed. MDR1 3435T was associated with drug-resistant epilepsy when haplotype analysis was performed (Hung et al., 2005; Seo et al., 2006) . Ethnic difference with regard to MDR1 C3435T gene polymorphism was observed, and this may indicate the role of other modifier genes influencing the expression of MDR1 (Siddiqui et al., 2003; Tan et al., 2004; Shahwan et al., 2007) . The high interpatient variability in MDR1 expression can cause substantial variation in both the rate and extent of absorption of orally administered drugs that are MDR1 substrates, including the AEDs. PHT is the most widely used anticonvulsant drug worldwide and it exhibits nonlinear pharmacokinetics. Tishler et al. (1995) demonstrated in resected glia that over-expression of MDR1 resulted in PHT drug resistance. We show here that MDR1 C3435T gene polymorphism regulates serum PHT levels in epileptic patients ( p < 0.01). An understanding of the physiological role of C3435T genetic alteration in MDR1 transporter will help improve the therapeutic efficacy of AEDs (Sukhai and PiquetteMiller, 2000) .
Over-expression of MDR1 in the endothelial cells of brain may efflux the drug back from endothelial cells into the blood, leading to inadequate levels of PHT in the brain and, hence, precipitate seizures. Effluxed PHT drug in the blood may also result in high serum levels of PHT as shown by elevated serum levels in CT and TT genotype carriers in the present study. CC genotype carriers showed low serum PHT levels, this might be explained by influx of drug into the brain and no active participation of MDR1 in effluxing the drug back into blood. These results corroborate the Hoffmeyer and coworkers (2000) published article showing the effect of the MDR1 3435T allele on bioavailability of digoxin. However, Allabi et al. (2005) showed the association of the 3435T allele with low levels of serum PHT. Some studies showed that the MDR1 C3435T gene polymorphism was not associated with refractory epilepsy (Leschziner et al., 2006; Dericioglu et al., 2008) . Further, it was observed that heterozygotes were highest with 15.74% (17/108) followed by 11.11% (12/108) of MDR1 TT genotype carriers. The overall results of the polymorphism studies carried out show that the MDR1 3435T allele plays a role in seizure occurrence of GS and FS. MDR1 C3435T gene polymorphism showed good correlation with the serum PHT levels, indicating a role in drug response of AEDs. Thus, the association of MDR1 3435T allele association with serum PHT levels observed in the present study is of clinical significance in the management of epileptic patients.
GABA is the main inhibitory neurotransmitter, and major AEDs used clinically act as GABAergic neurotransmission enhancers (Korpi et al., 2002) . Disruption of GABAergic neurotransmission mediated by GABA has been implicated in epilepsy, and the nature of the mutant channel may modulate the response to a given treatment (Wallace et al., 2001; Bowser et al., 2002) . In GABRG2, two reported mutations have been associated with generalized epilepsy with FS plus and two others with FS and childhood absence epilepsy (Baulac et al., 2001; Wallace et al., 2001; Ito et al., 2006) . The present study was conducted to evaluate the GABRG2 C588T gene polymorphism in GS and FS patients to assess whether it confers any susceptibility to seizures.
Allele frequency of control population in the present study was similar to the German and Nigerian population. However, Japanese, Chinese, and European populations carried a high frequency of the T allele. From the results of the present study, it was evident that the GABRG2 588T allele was associated with seizure occurrence. To the best of our knowledge, this is the first report from the Indian population that assesses FS association with GABRG2 C588T gene polymorphism.
Approximately 30% of children with FS experience one or more SRs during subsequent bouts of fever. In 30% of patients with epilepsy, the seizures persist despite regular and adequate AED and carefully monitored treatment (Regesta and Tanganelli, 1999) . Hence, it is clinically important to understand the underlying mechanism of SR for proper management of patients. As shown earlier in this study that the T allele was associated with seizure occurrence, TT and CT genotype carriers of SR group of GS and FS, respectively, are at a higher risk of developing recurrent seizure. As yet, there are no studies reporting the role of GABRG2 C588T gene polymorphism in association with SR.
From our study, we recommend dose adjustment based on MDR1 C3435T genotyping at the induction of therapy, and GABRG2 C588T genotyping would help in better patient management.
